Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy

Business France Japan Office of the French Embassy in Japan engages in building partnerships between Japanese and French Companies. Together with the Aderly (Agence pour le développement économique de la région lyonnaise), the embassy tries to match companies concentrating on cancer treatment, which resulted in a business exchange meeting of Stella Pharma presenting BNCT to delegation from the Centre Léon Bérard (CLB), headed by Dr Patrick Mehlen, a director of the Cancer Research Center of Lyon (CRCL).

The CLB is a comprehensive well-known cancer healthcare and research institution, located in France’s second largest city Lyon, and they conduct basic to international joint research, clinical trials as well as drug development.

 In its effort to continuously evaluate new cancer drug therapies and technologies, the CLB is interested to study the potential benefits of BNCT with regards to the latest studies in Japan.

Our company with the BNCT drug approval ahead of the world is willing to extend this treatment option also to hospitals outside Japan, and spread globally the knowledge and development of our product, Steboronine®.